Aclarion (ACON) Projected to Post Earnings on Wednesday

Aclarion (NASDAQ:ACON) is expected to announce its Q4 2025 results before the market opens on Wednesday, February 25th. Analysts expect Aclarion to post earnings of ($3.60) per share and revenue of $0.02 million for the quarter. Interested persons can check the company’s upcoming Q4 2025 earning summary page for the latest details on the call scheduled for Friday, March 20, 2026 at 10:30 AM ET.

Aclarion Trading Down 2.0%

Shares of ACON opened at $2.49 on Tuesday. The company has a market capitalization of $2.12 million, a PE ratio of -0.17 and a beta of 1.44. Aclarion has a 12 month low of $2.34 and a 12 month high of $229.50. The stock’s 50-day moving average price is $4.13 and its two-hundred day moving average price is $6.19.

Analyst Ratings Changes

A number of equities analysts have recently issued reports on the company. Weiss Ratings restated a “sell (e+)” rating on shares of Aclarion in a research report on Wednesday, January 21st. Wall Street Zen raised shares of Aclarion from a “sell” rating to a “hold” rating in a research report on Sunday. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the company has an average rating of “Sell”.

About Aclarion

Aclarion, Inc, a healthcare technology company, leverages for Magnetic Resonance Spectroscopy (MRS) in the United States. It develops NOCISCAN Post-Processor suite of software applications comprising NOCICALC that receives the raw un-processed NOCISCAN MRS exam data and post-processes that raw data into final spectra and performs various degenerative pain biomarker; and NOCIGRAM, a clinical decision support software. The company was formerly known as Nocimed, Inc and changed its name to Aclarion, Inc in December 2021.